GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jenscare Scientific Co Ltd (HKSE:09877) » Definitions » Retained Earnings

Jenscare Scientific Co (HKSE:09877) Retained Earnings : HK$-1,515.96 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Jenscare Scientific Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Jenscare Scientific Co's retained earnings for the quarter that ended in Jun. 2024 was HK$-1,515.96 Mil.

Jenscare Scientific Co's quarterly retained earnings declined from Jun. 2023 (HK$-1,214.02 Mil) to Dec. 2023 (HK$-1,428.38 Mil) and declined from Dec. 2023 (HK$-1,428.38 Mil) to Jun. 2024 (HK$-1,515.96 Mil).

Jenscare Scientific Co's annual retained earnings declined from Dec. 2021 (HK$0.00 Mil) to Dec. 2022 (HK$-1,043.21 Mil) and declined from Dec. 2022 (HK$-1,043.21 Mil) to Dec. 2023 (HK$-1,428.38 Mil).


Jenscare Scientific Co Retained Earnings Historical Data

The historical data trend for Jenscare Scientific Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jenscare Scientific Co Retained Earnings Chart

Jenscare Scientific Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
- - -1,043.21 -1,428.38 -

Jenscare Scientific Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only -1,043.21 -1,214.02 -1,428.38 -1,515.96 -

Jenscare Scientific Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Jenscare Scientific Co  (HKSE:09877) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Jenscare Scientific Co Business Description

Traded in Other Exchanges
N/A
Address
No. 777 Binhai 4th Road, Block 5, B Area, Hangzhou Bay New Area, Zhejiang Province, Ningbo, CHN
Jenscare Scientific Co Ltd is a China-based company mainly engaged in the manufacturing and research and development of medical devices. The company develops interventional products for the treatment of structural heart disease. The company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure.
Executives
Li Hui 2501 Other
Trident Trust Company (hk) Limited 2301 Trustee
Trinity Elite I International Limited 2201 Interest of corporation controlled by you
Lv Shiwen 2501 Other
Ningbo Dixiang Venture Capital Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Shidi Industrial Development Co., Ltd. 2501 Other
Pan Fei 2201 Interest of corporation controlled by you
Shanghai Jiachen Investment Co.,ltd 2201 Interest of corporation controlled by you
Ningbo Sangdi Investment Management L.p. (limited Partnership) 2101 Beneficial owner
Ningbo Linfeng Biotechnology Co., Ltd. 2101 Beneficial owner
Hainan Yize Medical Technology Co., Limited 2201 Interest of corporation controlled by you
Hainan Maidi Enterprise Management L.p. (limited Partnership) 2101 Beneficial owner
Hainan Hualing Investment L.p. (limited Partnership) 2101 Beneficial owner
Hangzhou Chende Investment Partnership (limited Partnership) 2101 Beneficial owner
Ningbo Mukang Venture Capital Partnership (limited Partnership)

Jenscare Scientific Co Headlines

No Headlines